The present invention provides compositions and methods that can be used to determine a peptide signature for an antibody repertoire in a sample comprising multiple antibodies. The method can be used to characterize a phenotype in a sample, such as providing a diagnosis, prognosis or theranosis of a medical condition.

A diagnostic method suitable for detection and quantification of blood-related diseases or conditions. The methods utilize biomarkers, such as hemoglobin and hemozoin as catalysts in an atom transfer radical polymerization (ATRP) reaction performed above a lower critical solution temperature (LCST) of a polymer which allows the polymerization to be tracked by rate of turbidity formation. The rate of turbidity formation is correlated to the concentration of the biomarker, making the tests useful quantitative techniques which can be utilized as point-of-care tests in the field.

Disclosed is a blood analyzer that includes: a sample preparation unit configured to mix a blood specimen and a fluorescent dye for staining nucleic acid to prepare a measurement sample; a light receiver configured to receive fluorescence and scattered light that are generated by light being applied to the measurement sample prepared by the sample preparation unit; and a controller programmed to determine whether or not infection with Plasmodium has occurred, on the basis of a value representing variation of a distribution of first particles in a range where single-ring form of red blood cells appear, the range where single-ring form of red blood cells appear being identified according to fluorescence intensities and scattered light intensities obtained by processing of signals from the light receiver.

A system, method, apparatus and diagnostic test for Plasmodium vivax, to determine a likelihood of a specific timing of infection by P. vivax in a subject, and hence identify individuals with a high probability of being infected with otherwise undetectable liver-stage hypnozoites. The system, method, apparatus and diagnostic test relate to the identification of hypnozoites (“dormant” liver-stages), or at least of the likelihood of the subject being so infected. Optionally and preferably, the specific timing relates to recent infections, for example within the last 9 months.

The present invention describes methods of identifying high-risk populations or individuals who have positive serology for T. gondii. These methods include obtaining a biological sample from a subject; determining the level of T. gondii cyst antigen antibody in the biological sample; and characterizing the biological sample in at least one of three categories.

Certain embodiments are directed to method for synthesizing and using glycoconjugates based on the immunodominant epitope Gal(1,3)Gal(1,4)GlcNAc (Gal3LN).

A diagnostic method suitable for detection and quantification of blood-related diseases or conditions. The methods utilize biomarkers, such as hemoglobin and hemozoin as catalysts in an atom transfer radical polymerization (ATRP) reaction performed above a lower critical solution temperature (LCST) of a polymer which allows the polymerization to be tracked by rate of turbidity formation. The rate of turbidity formation is correlated to the concentration of the biomarker, making the tests useful quantitative techniques which can be utilized as point-of-care tests in the field.

A method of using microfluidic chips to significantly accelerate the time to identify and quantify microbes in a biological sample and test them for antibiotic resistance, particularly for urinary tract infections. A first microfluidic chip uses antibody or similar probes to identify and quantify any microbes present. The same or a similar chip uses antibody or similar probes to identify microbes with DNA or RNA known to indicate antibiotic resistance. Another microfluidic chip tests for antibiotic susceptibility of any microbes by growing them in very small wells in the presence of antibiotics, reducing the time required for such testing by as much as 95%. Another microfluidic chip runs traditional urinalysis or similar tests.

The present invention provides compositions and methods that can be used to determine a peptide signature for an antibody repertoire in a sample comprising multiple antibodies. The of an antibody specificity in method can be used to characterize a phenotype in a sample, such as providing a diagnosis, prognosis or theranosis of a medical condition.

The present invention provides compositions and methods that can be used to determine a peptide signature for an antibody repertoire in a sample comprising multiple antibodies. The method can be used to characterize a phenotype in a sample, such as providing a diagnosis, prognosis or theranosis of a medical condition.